Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out
PLOS One · 2025
DOI: 10.1371/journal.pone.0332617 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Danny Wilbie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Aurora Kinase A, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Scientific Research (NWO) Talent program VICI, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
CRISPR gene therapy holds the potential to cure a variety of genetic diseases by causing a targeted DNA break, which is repaired by host DNA damage responses. One option to introduce precise gene corrections is via the homology-directed repair (HDR) pathway. The problem in utilizing this pathway is that CRISPR-induced double stranded DNA breaks are more likely to be erroneously repaired by the non-homologous end joining (NHEJ) pathway, which may introduce random insertions or deletions at the cut site. We screened a small library of oncological drug compounds to steer the DNA repair process towards preferential HDR activation. We included forty compounds in the screen based on their mechanism of action. After optimizing the toxicity and adding these compounds during gene editing, nine showed a potential benefit for HDR activation. Three were shown to be beneficial after validation: rucaparib, belinostat and alisertib. The Aurora Kinase A inhibitor alisertib in particular led to an over 4-fold increase in preferential gene correction over gene knock-out in two cell models (HEK293T and Hepa 1–6) at sub-micromolar dosages on the eGFP locus, prompting further validation. On the long term this pathway did show cytotoxicity especially in the HEK293T cells, indicating further mechanistic investigation is needed, but this toxicity was less pronounced in primary hepatocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- CDL Research, University Medical Center Utrecht, Utrecht, the Netherlands.
ORCID-Profile: Danny Wilbie
Förderung
- Netherlands Organisation for Scientific Research (NWO) Talent program VICI
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Wilbie, D., Eising, S., Amo-Addae, V., Walther, J., Bosman, E., Lei, Z., de Jong, O. G., Molenaar, J. J., & Mastrobattista, E. (2025). Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out. PLOS One. https://doi.org/10.1371/journal.pone.0332617
Vancouver
Wilbie D, Eising S, Amo-Addae V, Walther J, Bosman E, Lei Z, et al. Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out. PLOS One. 2025. doi:10.1371/journal.pone.0332617
BibTeX
@article{Wilbie2025,
author = {Wilbie, Danny and Eising, Selma and Amo-Addae, Vicky and Walther, Johanna and Bosman, Esmeralda and Lei, Zhiyong and de Jong, Olivier G and Molenaar, Jan J and Mastrobattista, Enrico},
title = {Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332617}
}
EUVIMED